Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations

Healthy Clinical Trial

Official title:

Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02643329
• Other study ID #: BABE-P14-095
• Status: Completed
• Phase: Phase 1
• First received: December 28, 2015
• Last updated: July 21, 2016
• Start date: January 2016
• Est. completion date: April 2016

Study information

• Verified date: July 2016
• Source: Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hong Kong: Department of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to compare the bioavailability of a generic product of gliclazide (Product Name: BF-Gliclazide Tablet 80mg, Manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited) with that of reference product (Product Name: Diamicron 80mg Tablet, Manufactured by Les Laboratoires Servier Industrie, France) when administered to healthy volunteers under fasting conditions. The plasma pharmacokinetic data of gliclazide obtained from two formulations will be used to access the interchangeability of the products.

Description:

The study design is a single-dose, two-treatment, two-period, two-sequence crossover with a washout period of one to two weeks. During each study session, healthy male subjects will be administered a single oral dose of 80 mg gliclazide (one BF-Gliclazide Tablet 80 mg or one Diamicron 80 mg Tablet) after an overnight fast of approximately 10 hours. 20% glucose will be given orally to each subject at 2 h after drug administration to minimize the risk of hypoglycaemia. Venous blood samples will be collected at pre-dose (0 h) and up to 72 hours post-dose. The plasma concentrations of gliclazide will be determined by a validated assay. The non-compartmental method will be used to analyze the plasma concentration-time data and calculate the main pharmacokinetic parameters such as Cmax, Tmax, AUC0-last, AUC0-inf and T1/2. ANOVA will be conducted on logarithmically transformed Cmax, AUC0-last and AUC0-inf. The two one-sided tests will be used to calculate the 90% confidence intervals for the mean difference in AUC0-last, AUC0-inf and Cmax, and to assess the bioequivalence of the two products.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: April 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Body Mass Index between 18 to 27

• Accessible vein for blood sampling

• High probability for compliance and completion of the study

• No significant abnormalities in general physical examination

• ECG recording within normal limits

• Biochemical and haematological parameters within normal limits

• Subjects must agree to take effective contraceptive methods to prevent his partner from becoming pregnant during the time of first dose of study medication until one week of last dose administration

Exclusion Criteria:

• History of hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to the study

• Clinically relevant abnormality in physical examination, ECG evaluation, urine test, blood chemistry or haematological test

• Tabacco use in any forms

• Regular consumer of alcohol

• Blood donation within 4 weeks prior to the start of the study

• Use of gliclazide within 4 weeks before the study

• Use of antidiabetic medications within 4 weeks before the study

• Volunteer in any other clinical drug study within 2 months prior to this study

• Hypersensitivity to gliclazide or other drugs in its class

• History of drug abude in any form

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• BF-Gliclazide Tablet 80mg
BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
• Diamicron 80mg Tablet
Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France

Locations

Country	Name	City	State
Hong Kong	Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong	New Territories

Sponsors (2)

Lead Sponsor	Collaborator
Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited	Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak plasma concentration (Cmax) of gliclazide		72 hours	Yes
Primary	Area under the plasma concentration versus time curve (AUC) of gliclazide		72 hours	Yes
Secondary	Time to maximum concentration (Tmax) of gliclazide		72 hours	Yes
Secondary	Elimination half-life (t1/2) of gliclazide		72 hours	Yes